10 completed, 4 terminated, 2 active not recruiting, 2 withdrawn. 19 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 10, Terminated 4, Active not recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Unknown 1 |
Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma lenalidomide, rituximab, parsaclisib - Follicular Lymphoma | Phase 1 | Withdrawn | Innovent Biologics (Suzhou) Co. Ltd. | 2023-07-28 | 2023-10-17 | |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma | Phase 1 | Terminated | Henan Cancer Hospital | 12 | 2022-02-20 | 2025-12-02 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. parsaclisib - Advanced Malignancies | Phase 1 | Completed | Incyte Corporation | 48 | 2021-05-04 | 2022-08-17 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. parsaclisib - Advanced Malignancies | Phase 1 | Completed | Incyte Corporation | 21 | 2021-03-29 | 2022-08-26 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib - Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma | Phase 1 | Active not recruiting | Mayo Clinic | 50 | 2020-06-15 | 2026-02-02 |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer Parsaclisib - Breast Cancer, Breast Neoplasms | Phase 1 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2020-06-01 | 2020-11-03 | |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma INCB053914, INCB050465 - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 9 | 2018-12-03 | 2020-11-10 |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Retifanlimab, Epacadostat, INCB050465 - Unresectable or Metastatic Solid Tumors | Phase 1 | Completed | Incyte Corporation | 83 | 2018-08-17 | 2023-02-21 |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Parsaclisib - Lymphoma | Phase 1 | Completed | Incyte Corporation | 17 | 2018-08-02 | 2023-08-14 |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Parsaclisib, Rituximab, Bendamustine - B-cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 50 | 2018-07-02 | 2025-08-21 |
| Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Parsaclisib, Hexal, Gazyvaro - Lymphoma | Phase 1 | Completed | Incyte Corporation | 26 | 2017-02-15 | 2025-08-21 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Pembrolizumab, itacitinib, INCB050465 - Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 | Completed | Incyte Corporation | 159 | 2016-01-25 | 2022-03-31 |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors Itacitinib, Epacadostat, INCB050465 - Solid Tumors | Phase 1 | Terminated | Incyte Corporation | 142 | 2015-11-01 | 2019-09-25 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 83 | 2014-09-10 | 2020-04-17 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (4) · Breast Neoplasms (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Mantle-Cell (2) · Recurrence (2) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1)
Incyte Corporation (12) · Fudan University (1) · Henan Cancer Hospital (1) · Incyte Biosciences Japan GK (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Mayo Clinic (1) · UNC Lineberger Comprehensive Cancer Center (1) · Walter Hanel (1)
United States (13) · Italy (3) · Spain (3) · Japan (2) · Austria (1) · Belgium (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1)
Carey Lisa, MD (1) · Cinthya Coronado, MD (1) · Claudia Corrado, M.D. (1) · Ekaterine Asatiani, M.D. (1) · Fitzroy Dawkins, MD (1) · Fred Zheng, MD (1) · Junning Cao (1) · Lance Leopold, MD (1) · Oliver Manzke, MD (1) · Peter B. Langmuir, MD (1) · Peter Langmuir, MD (1) · Walter Hanel, MD, PhD (1) · Yanyan Liu, M.D. Ph.D (1) · Yucai Wang, M.D., Ph.D. (1)
PMID 30803990, PMID 35288468, PMID 38115208, PMID 38598516, PMID 41563911, PMID 42827632
2016 (1), 2017 (1)